The scrutiny follows a July 21, 2026, announcement in which Agios disclosed the topline results from a Phase 2 trial of tebapivat. The company admitted the drug failed to demonstrate the level of differentiation required for continued development, forcing an immediate halt to the program. The market reaction was swift, with Agios shares dropping $2.70—a 6.74% decline—to close at $37.36 that same day.

Pomerantz LLP is now reviewing whether these developments, coupled with earlier corporate disclosures, constitute a breach of fiduciary duty or unlawful business practices. Investors who suffered losses are being urged to contact Danielle Peyton to discuss potential participation in a class action lawsuit.